|Articles|December 5, 2014
Innocutis has launched its newest product, Sitavig
Advertisement
INNOCUTIS has launched its newest product, Sitavig (acyclovir) 50 mg buccal tablets. Sitavig uses Lauriad technology, which consists of a tablet that sticks to the gum, above the canine tooth on the side of the lip that is infected with a cold sore, according to the company. This white- to slightlyyellow tablet is tasteless and odorless. It dissolves to provide a sustained release of medicine.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
2
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
3
Expert Panel Unanimously Backs DecisionDx-Melanoma for Guiding Personalized Cancer Care
4
Considering Biologics and Shared Decision-Making in Moderate to Severe Plaque Psoriasis: Part 2
5













